New Data Prompt FDA Review Period Extension for Omecamtiv Mecarbil
The FDA extended the action date by 3 months to review additional pharmacokinetic analyses provided by the Company.
CHF and Arrhythmias
IV Vitamin C Increases Risk for Death, Organ Failure in Sepsis
Risk increased with intravenous vitamin C versus placebo for adults with sepsis in the ICU receiving vasopressor therapy
COVID-19 Vaccines Cut Mortality With Heart Failure
Those who are partially vaccinated and unvaccinated face same increased risk, while boosted and fully vaccinated adults fare best
Heart Failure Hospitalization Risk Compared With Empagliflozin vs Other Glucose-Lowering Txs
The EMPRISE study assessed the efficacy and safety of empagliflozin use in approximately 500,000 adults with type 2 diabetes.
Updates Issued for Standards of Medical Care in Diabetes
Updates include effects in T2D patients of finerenone on CV outcomes in those with CKD; of SGLT2 inhibitors on heart failure, renal outcomes
NDA Submitted for Landiolol, a Highly Cardioselective Beta Blocker
Landiolol is an ultra-short acting, cardioselective, beta-1 adrenoceptor blocker designed to reduce heart rate with a minimal effect over cardiac contractility.
Metformin, Lifestyle Changes Cut Risk for T2DM, But Not CVD
No reduction seen in first occurrence of nonfatal MI, stroke, or CV death with either metformin or lifestyle intervention versus placebo
Aspirin May Lower Cardiovascular Risks in Chronic Kidney Disease Population
Aspirin use among patients with chronic kidney disease was associated with reduced risk for major adverse cardiovascular events.
Gout Drug May Cut Mortality in Heart Failure Hospitalizations
In-hospital mortality rate lower for patients with acute heart failure exacerbation who received colchicine for gout flare
Risk for Hospitalization for Heart Failure Down With SGLT-2i Treatment for T2D
Risk for stroke, MI, all-cause mortality similar for those initiating SGLT-2i or metformin
